The Role of RANKL and FGF23 in Assessing Bone Turnover in Type 2 Diabetic Patients

Nita, G.; Niţă, Otilia; Gherasim, Andreea; Li, Arhire; Am, Herghelegiu; Mihalache, Laura; Tuchiluş, Cristina; Graur, Mariana

doi:10.4183/aeb.2021.51

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RANKL is associated with macroangiopathy in diabetic patients, and patients with diabetic macroangiopathy have higher concentrations of RANKL in their bodies (27). Trials have also shown that RANKL is involved in macroangiopathy in diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined Type 2 diabetes mellitus

Ke Wang,

Liu Gao,

Chang Liu

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined Type 2 diabetes mellitus

Ke Wang,

Liu Gao,

Chang Liu

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Vachliotis

Polyzos

2023

Curr Obes Rep

View full text Add to dashboard Cite

Purpose of Review To summarize evidence on the potential involvement of the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (NF-κΒ) ligand (RANKL)/receptor activator of NF-κΒ (RANK) axis in the pathogenesis of metabolic diseases. Recent Findings The OPG-RANKL-RANK axis, which has been originally involved in bone remodeling and osteoporosis, is now recognized as a potential contributor in the pathogenesis of obesity and its associated comorbidities, i.e., type 2 diabetes mellitus and nonalcoholic fatty liver disease. Besides bone, OPG and RANKL are also produced in adipose tissue and may be involved in the inflammatory process associated with obesity. Metabolically healthy obesity has been associated with lower circulating OPG concentrations, possibly representing a counteracting mechanism, while elevated serum OPG levels may reflect an increased risk of metabolic dysfunction or cardiovascular disease. OPG and RANKL have been also proposed as potential regulators of glucose metabolism and are potentially involved in the pathogenesis of type 2 diabetes mellitus. In clinical terms, type 2 diabetes mellitus has been consistently associated with increased serum OPG concentrations. With regard to nonalcoholic fatty liver disease, experimental data suggest a potential contribution of OPG and RANKL in hepatic steatosis, inflammation, and fibrosis; however, most clinical studies showed reduction in serum concentrations of OPG and RANKL. Summary The emerging contribution of the OPG-RANKL-RANK axis to the pathogenesis of obesity and its associated comorbidities warrants further investigation by mechanistic studies and may have potential diagnostic and therapeutic implications.

show abstract

Body Composition Changes in Men With HIV/HCV Coinfection, HIV Monoinfection, and HCV Monoinfection

Barbu¹

2022

Acta Endo (Buc)

View full text Add to dashboard Cite

The Role of RANKL and FGF23 in Assessing Bone Turnover in Type 2 Diabetic Patients

Cited by 3 publications

References 38 publications

Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined Type 2 diabetes mellitus

Denosumab improves glycaemic parameters in postmenopausal osteoporosis patients with combined Type 2 diabetes mellitus

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Body Composition Changes in Men With HIV/HCV Coinfection, HIV Monoinfection, and HCV Monoinfection

Contact Info

Product

Resources

About